INTRODUCTION

LG Growth Study (LGS) is an open-label, multicenter, observational study which has begun in November 2011 to evaluate the long-term safety and effectiveness of recombinant human growth hormone (rHGH) treatment in Korean pediatric patients with growth disorders including growth hormone deficiency (GHD), idiopathic short stature (ISS), small for gestational age (SGA), Turner Syndrome (TS) and chronic renal failure (CRF).

AIM

This study aimed to analyze dosing patterns of recombinant human growth hormone (rHGH) (Eutropin® Inj., Eutropin® Pen Inj., and Eutropin® AQ Inj. for daily injection, and NordiNet® Inj. for daily injection, and NordiNet® Pen Inj. for weekly injection, LG Chem, Ltd.) using the collected data of the LG Growth Study (LGS).

METHOD

The LGS data collected until March 2020 was used for this analysis. Actual GH dose was calculated descriptively across indications and to labeled dose per each indication in Korea. All reported adverse events (AEs) across indications were assessed. Also the literary comparison of actual GH dose pattern with those from other observational studies in USA and European countries (NordiNet® IOS and ANSWER Program) was done.

CONCLUSIONS

In this study, GHD pediatric patients received a slightly higher dose than labeled recommendations while patients with ISS, SGA and TS were treated with lower doses of GH than the labeled dose. And the incidence rate of AEs was not correlated with the dosing patterns across the indications.

REFERENCES


ACKNOWLEDGEMENTS

This cohort study was sponsored by LG Chem, Ltd. (http://www.lgchem.com/global/main).

CONTACT INFORMATION

Dr. H.S. Lee: season@ajou.ac.kr or lggosmb@lgcpartner.com